BJH - volume 15, issue 7, november 2024
S. Marchetta MD, C. Douin MD, T. Couvreur MD, J. Djekic MD, B. Bastens MD, G. Houbiers MD, B. Massart MD, R. Roufosse MD, L. Longrée , C. Focan MD, PhD
The authors report the case of a patient suffering from cardiac amyloidosis with hepatic involvement. A prolonged remission was obtained under chemoimmunotherapy with CyBorD association (cyclophosphamide, bortezomib, and dexamethasone) and daratumumab. A literature survey is performed and presented.
Top
